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Gaia Schiavon1,2* and Ian E Smith1,2Abstract
Adjuvant endocrine therapy reduces the risk of
recurrence and death from breast cancer in women
with hormone receptor-positive early breast cancer.
Tamoxifen has been the standard therapy for decades,
and this is still the case for pre-menopausal women.
Ovarian suppression is of similar efficacy but currently
there is no strong evidence for adding this to tamoxifen
and the additional morbidity can be considerable.
Results from two important trials addressing this issue
are imminent. In post-menopausal women, aromatase
inhibitors (AIs) (letrozole, anastrozole, or exemestane)
are superior to tamoxifen in preventing recurrence but
only letrozole has been shown to improve survival. The
main gain is against high-risk cancers, and tamoxifen
gives very similar benefit for low-risk disease. Traditionally,
treatment has been given for around 5 years, but many
women remain at risk of relapse for 10 years or more.
The AIs, and more recently tamoxifen, have been shown
to reduce further the risk of late recurrence in women
still in remission after 5 years of tamoxifen if given for a
further 5 years. The comparative benefits of these two
options and the selection of patients most likely to
benefit from long-term adjuvant endocrine therapy are
important topics for further research, as is the optimum
duration of AI therapy started upfront.Introduction
Adjuvant endocrine therapy, usually today with tamoxi-
fen or an aromatase inhibitor (AI), is standard treatment
for estrogen receptor-positive (ER+), early-stage breast
cancer (BC), which accounts for approximately 75% of
BC [1]. This is by far the oldest effective systemic
treatment for any cancer, and Figure 1 illustrates the* Correspondence: gaia.schiavon@icr.ac.uk
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2014evolution of endocrine therapy, starting with Thomas
William Nunn in the 1880s [2].First trials: oophorectomy
Oophorectomy - or ovarian ablation (OvA) - was the
first form of systemic treatment for BC [3]. Although
the interpretation of many trials testing OvA is limited
by the small sample size or study design, their combined
analysis (using age as a surrogate for menopausal status)
through the Early Breast Cancer Trialists’ Collaborative
Group (EBCTCG) has unequivocally established that
OvA as a single intervention reduces recurrence and in-
creases survival for women younger than 50 years of age
for both axillary node-positive and node-negative disease
[4]. By indirect comparison, the magnitude of the benefit
was similar to that seen with adjuvant chemotherapy or
tamoxifen (see below) [5,6].Adjuvant tamoxifen
First trials
Results of the first randomized trials - Nolvadex Adjuvant
Trial Organization, Cancer Research Campaign Adjuvant
Breast Trial, National Surgical Adjuvant Breast and Bowel
Project (NSABP) B-14 - showing the benefit of tamoxifen
as adjuvant treatment in early BC are shown in Figure 1
[7-11].Tamoxifen and the Oxford overview
The first Oxford EBCTCG meta-analysis involved al-
most 30,000 women in 28 trials with either node-
positive or node-negative BC who were randomly
assigned to tamoxifen (or not) for about 5 years [12].
It demonstrated a clear reduction in mortality in
women at least 50 years of age treated with tamoxifen
(P <0.0001) and a reduction in the annual odds of
death during the first 5 years of about 20%. Subse-
quent analyses showed that the proportional risk re-
ductions produced by tamoxifen were little affected
by entry age or nodal status [13].Central Ltd. The licensee has exclusive rights to distribute this article, in any
n. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Adjuvant endocrine therapy history: the first key steps. The first steps in the evolution of endocrine therapy are presented. *In
seven of these trials, the ovarian ablation (OvA) and control groups received no routine cytotoxic chemotherapy, in one there were random
assignments both for cytotoxic therapy and for OvA in a ‘factorial’ design, and in four both groups were scheduled to receive a common
cytotoxic chemotherapy regimen (after OvA, in those allocated this treatment). BC, breast cancer; BD, bis die (twice daily); CRC, Cancer Research
Campaign; EBC, early breast cancer; EBCTCG, Early Breast Cancer Trialists’ Collaborative Group; ER, estrogen receptor; i.v., intravenously; NATO,
Nolvadex Adjuvant Trial Organization; NSABP, National Surgical Adjuvant Breast and Bowel Project; OS, overall survival; OvS, ovarian suppression;
RFS, recurrence-free survival; yr, year (s).
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findings. The most recent meta-analysis with a me-
dian follow-up of 13 years showed that, in ER+ dis-
ease, tamoxifen for about 5 years achieved a
reduction of yearly BC mortality of about a third
throughout the first 15 years (rate ratio (RR) 0.70, P
<0.00001). The RRs were 0.53 in years 0 to 4 and
0.68 in years 5 to 9, and there was no subsequentloss of the gains made during the first decade. Over
all time periods, the recurrence rate reduction aver-
aged 39% (RR = 0.61 for any recurrence, and 0.62 for
contralateral disease incidence; both two-sided P
<0.00001) [14]. The relapse curves did not converge
after year 10 (RR = 0.97 in years 10 to 14); therefore,
a high proportion of patients receiving tamoxifen for
5 years can be potentially cured.
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BC mortality was significantly reduced by tamoxifen in
each age group with 15-year gains of 10.6%, 4.6%, 11.7%,
and 17.4%, respectively, in the ages at entry of less than
45, 45 to 54, 55 to 69, and ≥70 years. Nodal status,
tumor grade, and diameter did not materially affect pro-
portional risk reductions, but they were of course pre-
dictive of the absolute risk without tamoxifen and hence
of the absolute benefit. Local recurrence, contralateral
BC (generally new primary), and distant recurrence were
all substantially reduced by tamoxifen (each P <0.00001).
Tamoxifen with chemotherapy
There were highly significant recurrence reductions both
in the six trials with no chemotherapy (RR = 0.56) and in
the 14 trials of chemotherapy plus tamoxifen versus the
same chemotherapy alone (RR = 0.67), and there was a
slightly greater effect of tamoxifen in those with greater
degrees of ER positivity in both trial categories [13].
Even if chemotherapy was given, tamoxifen was of sub-
stantial further benefit (that is, chemotherapy plus tam-
oxifen was better than chemotherapy alone), producing
a further reduction of about a quarter in 10-year recur-
rence risk, whether it was started concurrently with the
chemotherapy (RR = 0.62) or after it (RR = 0.71). The
slight superiority of starting concurrently was, however,
not significant, and these tamoxifen trials did not
randomize timing. In all regimens, tamoxifen had a sub-
stantial effect.
Significance of progesterone receptor
ER and progesterone receptor (PgR) status were strongly
associated. PgR (when measured) was positive in 76% of
ER+ and only 21% of ER− (strictly, ER-poor) disease. Pa-
tients with ER+PgR− disease had just as good a propor-
tional benefit with tamoxifen (RR = 0.60) as those with
ER+PgR+ (RR = 0.63) (both 2P <0.00001). The absolute
recurrence reduction at 15 years seemed, if anything,
greater in ER+PgR-poor than in ER+PgR+ disease, per-
haps because of the higher background risk of recur-
rence without treatment.
The RR was 0.90 for ER−PgR+ disease (2P = 0.35). As
assays improve, progressively fewer BCs are reported as
ER−PgR+ where repeat testing on another tissue sample
has been recommended, and it is likely that many of
these are artefactual.
Tamoxifen in ER-negative and ER-low breast cancer
Tamoxifen was of no benefit where ER measurement was
zero (RR = 0.97 for any recurrence; RR = 0.94 for contra-
lateral disease). However, tamoxifen was beneficial at ER
concentrations as low as 10 fmol/mg of cytosol protein
with improving efficacy at increasing ER measurements.Recent guidelines suggest an immunohistochemistry cut-
off of 1% to define a tumor as ER+ [15].
Duration: 5 years or less
Both direct [13] and indirect [14] comparisons showed
greater mortality reduction with approximately 5 versus 2
years of tamoxifen. Reductions in recurrence and mortal-
ity during years 0 to 4 were almost as great for shorter
treatment duration but were less during years 5 to 9. Al-
though the combined effects of patient drop-out and
drop-in cannot be quantified exactly, the RR for BC death
of 0.70 in the meta-analyses of outcome by allocated treat-
ment suggests that in ER+ disease full compliance with 5
years of tamoxifen would reduce 15-year BC mortality
rates by at least a third and probably more. The important
issue of tamoxifen for more than 5 years is discussed
below (‘Extended adjuvant endocrine therapy’).
Toxicities
Tamoxifen and the AIs (see below) are generally well tol-
erated with a low incidence of serious adverse effects
(SAEs). The two serious toxicities with tamoxifen are
endometrial cancer and thromboembolic events [16]. The
increased uterine cancer incidence has an RR of 2.40 (P =
0.00002) without significant effect on other cancers [14].
The uterine cancer risk was strongly correlated with
age, with little absolute risk for entry age of less than 45
years or 45 to 54 years. For entry age of 55 to 69 years,
15-year incidence rates were 3.8% in the tamoxifen
group and 1.1% in the control group (absolute increase
of 2.6%). In ER+ disease, there were nine deaths in the
tamoxifen group and one in the control group from
uterine cancer and six versus no deaths from pulmonary
embolus (PE) during the first 5 years (but no apparent
excess afterwards). A non-significant excess of stroke
deaths (3 extra per 1,000 women during the first 15
years, none of which occurred during the treatment
period) was balanced by a non-significant shortfall in
cardiac deaths (3 fewer per 1,000 women during the first
15 years); so little net effect on overall vascular mortality
was recorded. For entry age of younger than 45 years,
intercurrent mortality was low, there were no deaths
from uterine cancer or PE in either group, and 15-year
gains in overall and BC mortality were similar.
CYP2D6 genotyping and tamoxifen efficacy
Tamoxifen is metabolized by the cytochrome P450 2D6
(CYP2D6) to 4-hydroxy tamoxifen and 4-hydroxy-N-
desmethyl tamoxifen (endoxifen), the latter metabolite
being the more abundant and more potent in terms of
ER-binding affinity and suppression of estradiol-
stimulated cell proliferation [17,18].
Therefore, CYP2D6-mediated metabolism is the rate-
limiting enzymatic step for the formation of endoxifen,
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influencing CYP2D6 enzyme activity with tamoxifen effi-
cacy has been investigated by several groups but with
conflicting results [19-24]. Recently, however, two large
randomized trials - Arimidex, Tamoxifen, Alone or in
Combination (ATAC) and Breast International Group
(BIG) 1-98 - have shown that CYP2D6 variant alleles do
not influence outcome on tamoxifen [21,22,25], and it is
our view that there is no clinical indication for measur-
ing these alleles in patients about to receive tamoxifen.
Adjuvant ovarian suppression
The 2005 Oxford Overview (but not the most recent in
2011) included 7,601 women (age of less than 50 years)
treated with either OvA (approximately 55%) or ovarian
suppression (OvS) with the luteinizing hormone-releasing
hormone (LHRH) (that is, goserelin) analogue, confirming
a reduction of approximately 30% in recurrence and BC
mortality [13]. The real benefit may be greater because
many of the women in these trials had unknown receptor
status. The risk reduction for women younger than 40
years was not significantly different from those who were
40 to 49. There was no significant difference in efficacy
between OvA and OvS, despite a slight trend against the
LHRH analogues. The benefit of OvA was sustained for
up to 15 years, and an absolute difference in recurrence
rate was 4.3%. This questions whether relatively short
LHRH analogue treatment used today for no more than 2
to 3 years is as effective as permanent ablation.
A more detailed systematic review focused on 16 adju-
vant randomized trials using LHRH agonists in 9,022 pa-
tients with hormone receptor-positive (HR+) BC (91.8%
were ER+ and the remainder were ER−PgR+) [26]. In these
trials, women were randomly assigned to receive an LHRH
agonist or not, and other comparisons were based on
chemotherapy or tamoxifen. Statistically significant reduc-
tion of recurrence (by 13%, P = 0.02) or death (by 15%, P =
0.03) after recurrence was observed when LHRH was added
to agonists to tamoxifen or chemotherapy (or both) but not
when used as the only systemic adjuvant treatment.
The relative merits of adjuvant OvS, tamoxifen, or the
two treatments combined are still controversial. A US
Intergroup trial (INT 0101) randomly assigned 1,503
pre-menopausal women pre-treated with chemotherapy
to control arm (no adjuvant endocrine therapy), 5 years
of goserelin, or 5 years of goserelin plus tamoxifen [27].
This showed a trend toward improvement in overall sur-
vival (OS) for goserelin versus control (hazard ratio =
0.88, P = 0.14) and a greater benefit for combined goser-
elin plus tamoxifen versus goserelin (disease-free sur-
vival (DFS): hazard ratio = 0.74, P <0.01 and OS: hazard
ratio = 0.91, P = 0.21), suggesting that there may be a
benefit of adding tamoxifen to goserelin on DFS but not
OS.The Austrian Breast and Colorectal Cancer Study
Group (ABSCG)-12, a randomized controlled multicen-
ter trial in 1,803 pre-menopausal women with HR+ BC
(all receiving adjuvant goserelin), compared the efficacy
and safety of anastrozole or tamoxifen with or without
zoledronic acid for 3 years [28]. Of note, these patients
did not receive any adjuvant chemotherapy, although ap-
proximately 5% of patients received neoadjuvant chemo-
therapy (balanced in the four arms). In regard to the
comparison of anastrozole versus tamoxifen, the DFS
was not different between the two arms, but patients
on anastrozole alone had shorter OS (hazard ratio = 1.75,
P = 0.02) at a median follow-up of 62 months (range of 0
to 114.4 months) [29]. Body mass index had a signifi-
cant impact on the efficacy of anastrozole plus goserelin
in these women [30]. The authors commented that
incomplete suppression of estrogen production in per-
ipheral body fat could be the cause of the reduced effect
of anastrozole in the overweight and obese groups of
patients. Unfortunately, the important clinical question
of whether there was any gain in adding goserelin to
tamoxifen was not addressed in any of the above-
mentioned trials.
Long-term follow-up (median of 12 years) of 2,706
women enrolled in the Zoladex In Pre-menopausal Pa-
tients trial showed no significant difference between 2
years of tamoxifen treatment versus 2 years of goserelin
versus 2 years of combined tamoxifen plus goserelin in
reducing the risk for an event (recurrence, new tumor,
or death) (RR = 29%, 33%, and 35%, respectively, com-
pared with no endocrine therapy) [31]. The P values for
the test of interaction between goserelin and tamoxifen
were 0.01 (any event), 0.13 (death from any cause), 0.016
(BC recurrence), and 0.17 (death from BC).
Two important ongoing randomized phase 3 trials -
Suppression of Ovarian Function Trial (SOFT) and
Tamoxifen and Exemestane Trial (TEXT) - are evaluat-
ing the addition of OvS to tamoxifen and also the role of
AIs in pre-menopausal women with ER+ early BC. SOFT
compares tamoxifen versus OvS plus tamoxifen versus
OvS plus exemestane for 5 years. OvS can be achieved
with gonadotropin-releasing hormone analog (triptore-
lin) for 5 years, oophorectomy or ovarian irradiation.
TEXT compares 5 years of OvS (triptorelin) plus tamoxi-
fen to OvS (triptorelin) plus exemestane. Primary ana-
lyses for both trials are expected in late 2014 to early
2015.
In summary, current data suggest that OvS is
equivalent to tamoxifen for patients in whom the lat-
ter is contraindicated, but so far there is no conclu-
sive evidence that OvS in addition to tamoxifen, or
indeed to chemotherapy, is of superior benefit, and
for many women this treatment can have an adverse
effect on quality of life.
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The development of inhibitors of aromatase, the enzyme
that synthesizes estrogens from androgens, has provided
an alternative strategy to deprive breast tumors of stimu-
lation by endogenous estrogens in post-menopausal
women whose ovaries are no longer active and in pre-
menopausal women in whom ovarian function has been
suppressed or the ovaries have been removed [32,33]. It
is important to note that AIs are ineffective in pre-
menopausal women with functioning ovaries [33].
Aminoglutethimide (AG) was the first AI to be de-
veloped for clinical use [34-36] and showed benefit
initially in advanced disease and then as adjuvant
therapy [37], but it also suppressed aldosterone and
had toxicities, including rash and somnolence. A ran-
domized clinical trial involving 2,021 post-menopausal
women receiving tamoxifen alone for 5 years or in
combination with AG for the first 2 years of treat-
ment showed no significant difference in 5-year DFS
and OS [38]. Moreover, more patients failed to
complete combination treatment (13.7%) because of
side effects compared with tamoxifen alone (5.2%,
P = 0.0001).
Today three third-generation AIs are approved for use:
anastrozole and letrozole are non-steroidal AIs that re-
versibly and non-covalently bind aromatase [39], and
exemestane is a steroidal AI that irreversibly and cova-
lently binds aromatase. All third-generation compounds
approach nearly complete suppression of total-body
aromatization and plasma estrogen levels [40,41]. In a
recent study, letrozole was found to inhibit whole-body
aromatization by greater than 99% in all 12 patients [41].
Third-generation AIs have been studied as adjuvant
therapy against tamoxifen in a series of randomized clin-
ical trials in post-menopausal women, both as frontline
treatment and after tamoxifen (Tables 1 and 2).
Arimidex, tamoxifen, alone or in combination
The ATAC trial was the first trial to present data com-
paring adjuvant tamoxifen with an AI, and its results
heralded a major change in the endocrine therapy of
post-menopausal women. Tamoxifen was compared with
anastrozole alone or with anastrozole plus tamoxifen for
5 years in 9,366 post-menopausal women, of whom
7,839 (84%) were known to be HR+ [42]. At a median
follow-up of 33.3 months, rates of 3-year DFS of 89.4%
for anastrozole and 87.4% for the tamoxifen alone (haz-
ard ratio = 0.83, P = 0.013) were seen. The combination
showed no significant difference to tamoxifen alone
(87.2%, hazard ratio = 1.02, P = 0.8). The DFS improve-
ment with anastrozole was seen in HR+ but not in HR−
patients. The incidence of contralateral BC was signifi-
cantly lower with anastrozole than with tamoxifen (odds
ratio 0.42, P = 0.007).After a median follow-up of 120 months, the long-
term superior efficacy and safety of anastrozole over
tamoxifen as initial adjuvant therapy were confirmed
[53]. There were significant improvements (both in the
whole cohort and in the HR+ subgroup) in the anastro-
zole group compared with the tamoxifen group for DFS,
time to recurrence (TTR), and time to distant recur-
rence (TTDR) (Table 2). In HR+ patients, absolute differ-
ences in TTR between anastrozole and tamoxifen
increased over time (2.7% at 5 years and 4.3% at 10
years) and recurrence rates remained significantly lower
on anastrozole than tamoxifen after treatment comple-
tion (hazard ratio = 0.81, P = 0.03), although the carry-
over benefit was smaller after 8 years. There was,
however, no significant difference in OS (hazard ratio =
0.95, P = 0.4) or in deaths after recurrence between ana-
strozole and tamoxifen.
Breast international group 1-98
The BIG 1-98 study involved the other third-generation
non-steroidal AI, letrozole, and compared 5 years of
monotherapy with tamoxifen or with letrozole or with se-
quences of 2 years of one of these agents followed by 3
years of the other. The primary core analysis included all
8,010 patients but did not include any events after the first
2 years (the time of the switch) for patients in the two se-
quential arms [43]. These results showed that letrozole
improved DFS and TTDR versus tamoxifen alone. After a
median follow-up of 25.8 months, 5-year DFS estimates
were 84.0% and 81.4%, respectively. Compared with tam-
oxifen, letrozole significantly reduced the risk of a DFS
event (hazard ratio = 0.81, P = 0.003) and the risk of dis-
tant recurrence (hazard ratio = 0.73, P = 0.001).
The OS analysis of this trial was problematic as patients
on the tamoxifen-alone arm were given the option to
cross over to letrozole once initial results became avail-
able. Different analytical tools were developed to over-
come this, including inverse probability of censoring
weighted (IPCW) analysis, which achieves better estimates
of relative treatment effects in the presence of selective
crossover [58,59]. At a median follow-up of 8.7 years from
random assignment, letrozole monotherapy was con-
firmed to be significantly better than tamoxifen, not just
for DFS but (in contrast to ATAC) for OS by both
intention to treat (ITT) and IPCW analysis (Table 2) [54].
Sequential aromatase inhibitor treatment after tamoxifen
Several trials - including Intergroup Exemestane Study
(IES), Arimidex-Nolvadex 95, ABCSG-8, and the Italian
Tamoxifen Anastrozole trial - have addressed the issue
of switching to an AI after 2 to 3 years of tamoxifen in
post-menopausal women with ER+ disease [46-49].
These have consistently shown benefit for the switch
and indeed tended to have lower hazard ratios for DFS
Table 1 Main prospective, randomized, phase III clinical trials testing adjuvant aromatase inhibitors
Study Design Arms Number Population (post-menopausal women) Primary
endpoint (s)
Monotherapy (versus tamoxifen)
ATAC [42] Double-blind A versus T versus T + A (5 years) 9,366 HR+ EBC DFSa, occurrence
of AEs
BIG 1-98 [43] Double-blind L versus T versus L→T versus T→L
(5 years)
8,010 HR+ EBC DFSb
TEAM [44,45] Open-label,
multinational
Upfront T versus E (2.75 years) 9,775 HR+ EBC DFSc
Sequential T→E versus E (5 years)
Sequential therapy
IES [46] Double-blind T→E versus T→T (5 years) 4,724 HR+ EBC DFSd
ARNO 95 [47] Open-label T (2 years)→ earsabears) versus T
(2 years)→ T (3 years)
979 HR+ EBC who received 2 years of T DFSa
ABCSG Trial 8
[48]
Open-label T (5 years) versus T (2 years)→A
(3 years)
3,714 HR+ EBC who received 2-3 years of T RFSe
ITA [49] Open-label, multi-
center
T (2-3 years)→A (5 years) versus T
(5 years)
448 HR+ (or unknown) node+ EBC who
received 2-3 years of T
RFSf
BIG 1-98 [43] Double-blind L versus T versus L→T versus T→L
(5 years)
8,010 HR+ EBC DFSb
TEAM [44] Open-label,
multinational
Upfront E (2.75 years) versus T 9,779 HR+ EBC DFSc
E (5 years) versus sequential T→E
Extended therapy
MA.17 [50] Double-blind L versus placebo 5,187 HR+ EBC who had received 4.5 to 6 years




Open-label A (3 years) versus no further
treatment
856 HR+ EBC who had received 5 years of
adjuvant T, with or without AG, for the
first 2 years of therapy
RFSh
NSABP-33 [52] Double-blind E (5 years) versus placebo
(5 years)
1,598 HR+ T1-3N1M0 EBC who were disease-free
after 5 years of adjuvant T
DFSa
aTime from random assignment to the occurrence of local or distant recurrence, new contralateral breast cancer, or death from any cause; btime from random
assignment to the first of the following events: invasive recurrence in local, regional, or distant sites; a new invasive cancer in the contralateral breast; any second
(non-breast) primary cancer; or death without a previous cancer event; ctimes from random assignment to the earliest documentation of disease relapse
(locoregional or distant tumor recurrence or ipsilateral or contralateral breast cancer) or death from any cause; dtime from random assignment to local or distant
breast cancer recurrence, new primary breast cancer, or death without recurrence (intercurrent death); etime from random assignment to the earliest occurrence
of local or distant recurrence or death as a result of any cause; ftime from random assignment to disease recurrence, including both locoregional and distant
recurrences (except contralateral breast cancer); gtime from random assignment to the recurrence of the primary disease (in the breast, chest wall, or nodal or
metastatic sites) or the development of a new primary breast cancer in the contralateral breast; hinterval between the start of treatment or of the observation
period and the first evidence of locoregional recurrence, contralateral breast cancer, or distant metastasis. →, switch to; A, anastrozole; ABCSG, Austrian Breast and
Colorectal Cancer Study Group; AE, adverse event; AG, aminoglutethimide; ARNO 95, Arimidex-Nolvadex 95; ATAC, Arimidex, Tamoxifen, Alone or in Combination;
BIG, Breast International Group; DFS, disease-free survival; E, exemestane; EBC, early breast cancer; HR, hormone receptor; IES, Intergroup Exemestane Study; ITA,
Italian Tamoxifen Anastrozole (trial); L, letrozole; NSABP, National Surgical Adjuvant Breast and Bowel Project; RFS, recurrence-free survival; T, tamoxifen; TEAM,
Tamoxifen Exemestane Adjuvant Multinational.
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(Tables 1 and 2). This led to the hypothesis that perhaps
a greater gain might be achieved by starting with tam-
oxifen and switching rather than starting with an AI.
However, this comparison was made directly through
random assignment in both the BIG 1-98 and the Tam-
oxifen Exemestane Adjuvant Multinational (TEAM) (see
below) trials and neither has shown any basis for this hy-
pothesis. In BIG 1-98, at a median follow-up of 8.0 years
from random assignment, there was no significant differ-
ence between one of the crossover arms (tamoxifen
followed by letrozole) versus letrozole alone, but there
was a trend against starting with tamoxifen and thenswitching (DFS hazard ratio = 1.07; OS hazard ratio =
1.10; both P = 0.36; Table 2) [54].
The multicenter TEAM trial, originally designed to
examine the efficacy of exemestane versus tamoxifen in
9,779 HR+ women [44], was revised in 2004, and pa-
tients on tamoxifen were switched to exemestane after
2.5 to 3 years, when the IES (Table 1) reported superior
results for a switch from tamoxifen to exemestane after
2 to 3 years [45]. At a median follow-up of 5.1 years
(60% of patients completed at least 5 years of follow-up),
there was no significant difference in outcome between
the two groups: DFS rates were 85% in the sequential
arm and 86% in the exemestane-alone arm (Table 2)
Table 2 Outcome results in the main phase III clinical trials testing adjuvant aromatase inhibitors














Monotherapy analysis (versus tamoxifen)
ATAC [53] 120-
month follow-up

















(0.73-0.98) P = 0.02
HR+ patients 0.95
(0.84-1.06) P = 0.4
BIG 1-98 [54] 8.1-
year follow-up
L versus T 0.53 (0.78-0.96)
P = 0.007



































ARNO 95 [47] 30.1-
month follow-up
T (2 years)→A





NA NA NA 0.53 (0.28-0.99)
P = 0.045

















(5 years) versus T
(5 years)
NA RFS 0.64 (0.44-0.94)
P = 0.02










NA L→T DRFI 1.14 (0.92-
1.42) P = 0.24
L→T BCFI 1.10 (0.91-


























L versus placebo 0.68 (0.56-0.83)
P <0.001






























E (5 years) versus
placebo (5 years)
0.68 P = 0.07 RFS 0.44 P = 0.004 NA NA NA
→, switch to; A, anastrozole; ABCSG, Austrian Breast and Colorectal Cancer Study Group; ARNO 95, Arimidex-Nolvadex 95; ATAC, Arimidex, Tamoxifen, Alone or in
Combination; BCFI, breast cancer-free interval; BCFS, breast cancer-free survival; BIG, Breast International Group; CI, confidence interval; DDFS, distant disease-free
survival; DFS, disease-free survival; DRFI, distant relapse-free interval; DRFS, distant relapse-free survival; E, exemestane; HR+, hormone receptor-positive; IPCW, In-
verse probability of censoring weighted; IES, Intergroup Exemestane Study; ITA, Italian Tamoxifen Anastrozole (trial); L, letrozole; NA, not available; NSABP, National
Surgical Adjuvant Breast and Bowel Project; OS, overall survival; RFS, recurrence-free survival; SCC, approach proposed by Shao and colleagues [57]; T, tamoxifen;
TEAM, Tamoxifen Exemestane Adjuvant Multinational; TTDR, time to distant relapse; TTR, time to relapse.
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in both arms. In summary, there is no therapeutic gain
in starting with tamoxifen and switching to an AI rather
than starting with an AI upfront.Sequential tamoxifen after an aromatase inhibitor
The other BIG 1-98 crossover arm also addressed the
question of tamoxifen after 2 to 3 years of letrozole. At a
median follow-up of 8.0 years from random assignment,
there was no significant difference between letrozole
followed by tamoxifen versus letrozole alone (DFS haz-
ard ratio = 1.06, P = 0.48; OS hazard ratio = 0.97, P =
0.79; Table 2) [54]. Therefore, the clinical implication is
that a woman who wishes to switch from an AI to tam-
oxifen after 2 to 3 years because of side effects or for
whatever reason can do so without adversely affecting
outcome, at least for up to 5 years of treatment.Aromatase inhibitor toxicities and comparative
toxicities with tamoxifen
AIs are associated with a higher incidence of musculo-
skeletal adverse events (MSAEs) (for example, myalgias
and arthralgias), bone fractures, and decreased bone
mineral density (BMD) [44,60-67]. In contrast, tamoxi-
fen is associated with a higher incidence of thrombo-
embolic and gynecological events (including endometrial
cancer) [44,55,60,68-70]. Table 3 summarizes the inci-
dence of treatment-related SAEs in the main adjuvant
trials comparing AIs with tamoxifen.
In the 10-year analysis of ATAC, fractures were more
frequent during active treatment in the anastrozole
versus tamoxifen arm (451 versus 351, OR = 1.33,
P <0.0001) but were similar in the post-treatment
follow-up period (110 versus 112, OR = 0.98, P = 0.9).
Treatment-related SAEs were less common on anastro-
zole than on tamoxifen (223 versus 369, OR = 0.57,
P <0.0001) but were similar after treatment completion
(66 versus 78, OR = 0.84, P = 0.3). Anastrozole was asso-
ciated with significantly less risk of endometrial cancer
than tamoxifen (P = 0.02). No significant differences in
non-BC deaths or in the incidence of other cancers were
found between groups.
In the BIG 1-98 trial, the incidence of treatment dis-
continuation (13.6% versus 11.9% of patients on letro-
zole and tamoxifen, respectively, P = 0.08) as a result of
an adverse event (AE) was greatest during the first 2
years of treatment and stabilized to an additional 1% to
2% per year for the remainder of the 5-year period.
Endometrial cancer was diagnosed during treatment in 4
(0.2%) versus 11 (0.6%) patients on tamoxifen and letro-
zole, respectively. No significant difference between the
two arms was observed regarding (non-breast) malig-
nancies or deaths without prior cancer events.In the TEAM study, generally, gynecological symptoms
and PE occurred more frequently in the sequential treat-
ment group than in the exemestane-only group and the
opposite was seen regarding the incidence of MSAEs (50%
versus 44%), osteoporosis, and fractures. Of note, the ob-
servation of increase in fractures with AIs has been made
in trials which started over two decades ago, before bone
health awareness, BMD testing, and bone agents (that is,
bisphosphonates) were available. In the more contempor-
ary MAP.3 breast cancer prevention trial comparing exe-
mestane versus placebo, the absence of excess fragility
fractures and total fractures and the ≥10% decreases in
areal BMD in the exemestane group were reassuring
[25,72]. Of note, similar baseline BMD in the two groups
and the use of bisphosphonate therapy both before and
during the study were reported in this study.
Several professional medical societies and organizations
have published guidelines for the use of bisphosphonates
in preventing and treating bone loss during AIs
[21,22,73-75]. Therefore, the simple adherence to imple-
mented standard medical practice (for example, bone
health monitoring and vitamin D and calcium supplemen-
tation when appropriate) should largely obviate the frac-
ture risk associated with AI use. Moreover, although AIs
increase the rate of bone turnover and decrease bone
density in post-menopausal women [76,77], these effects
seem to diminish after completing AI therapy [78,79].
Regarding compliance, Cuzick and colleagues [80], in
contrast with other investigators, noted better treatment
adherence in patients experiencing vasomotor symptoms
and joint symptoms. Toxicity may depend on the kind
of patient reporting these symptoms and may be related
to treatment compliance, which would explain improved
treatment outcomes in these patients [81].
Interestingly, in 9,325 patients enrolled in the TEAM
trial [82], patients with specific AEs - including vasomotor
symptoms, MSAEs, and vulvo-vaginal symptoms - had
significantly better DFS and OS at multivariate analysis
and fewer distant metastases than patients reporting non-
specific or no AEs (Table 4). Increasing numbers of spe-
cific AEs were also significantly associated with better sur-
vival outcomes. Similarly, a recent retrospective analysis of
the BIG 1-98 trial suggests that the occurrence of arthral-
gia/myalgia/carpal tunnel symptoms at 3 and 12 months
is associated with a significantly better DFS and BC-free
interval irrespective of treatment (letrozole or tamoxifen)
[83]. Certain specific AEs may be valuable predictors and
biomarkers of treatment efficacy, although further pro-
spective investigation is warranted.
Cognitive function with aromatase inhibitors
While many patients report ‘chemotherapy fog’ mani-
festing as a decrease in short-term memory during
chemotherapy [84], less is known about the potential
Table 3 Incidence of treatment-related serious adverse events in the main adjuvant aromatase inhibitor trials [71]














ATAC A versus T 6,241 A versus T (5 years) 197 A versus T 6,186 A versus T (5 years)
6,186
A versus T (5 years) 6,186
Arthralgia: 35.6 versus
29.4 (<0.0001)
LS: −6.1 versus +2.8
(<0.0001)




35.7 versus 40.9 (<0.0001)




CTS: 3.0 versus 1.0
(<0.0001)
Hip: −7.2 versus +0.7
(<0.0001)




DVT event: 1.6 versus 2.4 (0.02) Reduced libido: 1.0
versus 0.4 (<0.0001)
CV deathc: 2.0 versus 2.0 (NR)






L versus T 8,028 (4,992)a NA L versus T 4,895 L versus T (6 years)
3,074
L versus T (6 years) 3,074
Arthralgia: 20.0 versus
13.5 (<0.001)




37.7 versus 42.9 (NR)
Myalgia: 7.1 versus 6.1
(0.19)




TE event: 2.0 versus 3.8 (<0.001)
Hypercholesterolemia: 50.6
versus 24.6 (<0.001)





LS: −2.8 versus +0.5
(0.0008)






1.6 versus 3.1 (<0.0001)
Hip: −2.2 versus +0.4 (0.04)
Vaginal discharge: 2.3
versus 6.8 (<0.0001)
FN: +0.3 versus −1.8 (0.414) Vaginal infection: 0.7
versus 2.2 (<0.0001)
MA.17 L versus placebo 5,187 L versus placebo 226 L versus placebo 5,187 L versus placebo (2.5
years) 5,187
L versus placebo 5,187
Arthralgia: 25.0 versus
21.0 (<0.001)
LS: −5.4 versus −0.7 (0.008) CV disease: 5.8 versus 5.6 (0.76) Vaginal bleeding: 6
versus 8 (0.005)
58 versus 54 (0.003)
Arthritis: 6.0 versus 5.0
(0.07)
Hip: −3.6 versus −0.7
(0.044)
MI: 0.3 versus 0.4 (NR) Stroke/
TIA: 0.7 versus 0.6 (NR)
Vaginal dryness: 6
versus 5 (0.26)
Myalgia: 15.0 versus 12.0
(0.0041)
TE event: 0.4 versus 0.2 (NR)
Hypercholesterolemia: 16 versus
16 (0.79)
aPatients analyzed; bvalues represent T-score change from baseline; cdata from 100-month analysis, n = 6,241; dincludes endometrial hyperplasia and neoplasia,
cervical neoplasm, and enlarged uterine fibroids. A, anastrozole; ATAC, Arimidex, Tamoxifen, Alone or in Combination; BIG, Breast International Group; BMD, bone
mineral density; CerebroV, cerebrovascular; CTS, carpal tunnel syndrome; CV, cardiovascular; DVT, deep vein thromboembolic; E, exemestane; FN, femoral neck; L,
letrozole; LS, lumbar spine; MI, myocardial infarction; MSK, musculoskeletal; NA, not available; NR, not reported; T, tamoxifen; TE, thromboembolic; TEAM, Tamoxi-
fen Exemestane Adjuvant Multinational; TIA, transient ischemic attack.
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Breast Cancer Action conducted an online survey in
1,199 women on AIs and found that approximately 2%
of the respondents experienced cognitive impairmentand that nearly half (48%) reported ‘mental fuzziness’
which led only 3% to stop taking their AI [85]. Few of
the large AI trials reported on cognitive function during
treatment, so available data are limited.
Table 4 Outcomes in relation to specific adverse events in the Tamoxifen Exemestane Adjuvant Multinational (TEAM)
trial [82]
Outcome measure AE Number of AEs (yes versus no AE) Hazard ratio 95% CI P value
DFS VMS 249 versus 837 0.731 0.618-0.866 <0.001
MSAE 239 versus 847 0.826 0.694-0.982 0.030
VVS 89 versus 997 0.769 0.585-1.01 0.058
Overall 418 versus 668 0.735 0.632-0.855 <0.001
OS VMS 147 versus 617 0.583 0.424-0.803 0.001
MSAE 151 versus 613 0.811 0.654-1.005 0.055
VVS 51 versus 713 0.570 0.391-0.831 0.003
Overall 268 versus 496 0.680 0.565-0.819 <0.001
DM VMS 165 versus 490 0.813 0.664-0.996 0.046
MSAE 138 versus 517 0.749 0.601-0.934 0.010
VVS 54 versus 601 0.687 0.435-1.085 0.107
Overall 261 versus 394 0.783 0.651-0.942 0.010
AE, adverse event; CI, confidence interval; DFS, disease-free survival; DM, distant metastases; MSAE, musculoskeletal adverse event; OS, overall survival; VMS, vaso-
motor symptoms; VVS, vulvovaginal symptoms.
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and verbal memory were reported in women on anastro-
zole as compared with healthy women [86]. A cross-
sectional study in 31 post-menopausal women with early
BC on anastrozole or tamoxifen for a minimum of 3
months [87] found significantly poorer verbal and visual
learning and memory in the anastrozole versus tamoxi-
fen group. These findings must be interpreted with cau-
tion because of the small sample size and use of a cross-
sectional design.
A prospective analysis from BIG 1-98 showed that
cognitive function was significantly better among pa-
tients on letrozole versus tamoxifen at the end of the 5-
year treatment period [88]. A second analysis comparing
the 5-year assessments with those collected about 1 year
later showed a significant improvement in cognitive
function of similar magnitude following completion of
endocrine therapy in both groups [89].
A neuropsychological cross-sectional study from the
TEAM trial evaluated the cognitive functioning during
the first year’s treatment [90]. In the exemestane group
(n = 62), 24% of patients reported reduced daily memory
functioning compared with 6% of healthy controls, but
there was no statistically significant difference between
the two groups in any cognitive domain after 1 year of
treatment [91]. Thus, the evidence of the effects of adju-
vant endocrine therapy on cognitive function is limited
and inconclusive, and further studies are required.
Predictive factors of benefit from an aromatase
inhibitor
As might be predicted, patients at highest risk based on
the number of involved nodes, tumor grade, size, vascu-
lar invasion, and Ki67 gained most from an AI comparedwith tamoxifen [64,92,93], and a recent subset analysis
of BIG 1-98 data also showed a more pronounced bene-
fit of letrozole in invasive lobular versus invasive ductal
carcinoma [94].
There is evidence from neoadjuvant studies suggesting
that ER+HER2+ (human epidermal growth factor receptor)
patients might respond better to AIs than to tamoxifen
[95-97]. However, although data from the TEAM trial sug-
gested a significant treatment-by-marker effect between
AI/tamoxifen treatment and HER1, 2, and 3 expression in
the 2.75 years prior to switching patients initially treated
with tamoxifen to exemestane [98], this was not observed
in the ATAC and BIG 1-98 trials. In these two trials, the
HER2 status did not predict for benefit from an AI versus
tamoxifen and patients with HER2-overexpressing or
-amplified tumors were found to have a worse prognosis
than HER2− patients, regardless of whether they received
tamoxifen or an AI [99,100]. Hence, the HER2 status is
not considered a selection criterion for the most appropri-
ate endocrine treatment.
Extended adjuvant endocrine therapy
Women with HR+ early BC are at continuous risk of re-
lapse up to 15 years after diagnosis, despite being on ad-
juvant endocrine therapy for around 5 years [13,101].
Several trials have addressed whether extended adjuvant
endocrine therapy beyond 5 years reduces the risk of late
recurrence.
NCIC CTG MA.17/BIG 1-97
NCIC CTG MA.17/BIG 1-97 tested the effectiveness of 5
years of letrozole after completion of the standard 4 to 6
years of adjuvant tamoxifen and was the first phase III trial
to demonstrate an OS advantage with an adjuvant AI [50].
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duction in the risk of recurrence was seen with letrozole
versus placebo (DFS hazard = 0.57, P = 0.00008) [50]. Based
on this, the safety monitoring committee recommended
study unblinding, allowing patients in the control group to
switch to letrozole (see below). At a median follow-up of 30
months, a relative reduction in recurrence risk of 42% oc-
curred with letrozole [63]. Letrozole treatment significantly
reduced the risk of distant metastases in both node-
negative and -positive patients (P = 0.002) and significantly
improved OS by 39% in node-positive patients compared
with placebo (hazard ratio = 0.61, P = 0.04). A further ITT
analysis of all outcomes, before and after unblinding, was
performed at a median follow-up of 64 months (Table 3).
Although 66% of women originally on placebo crossed over
to letrozole, a 32% reduction in the hazard for a DFS event
persisted for women originally randomly assigned to receive
letrozole [102]. More recently, Jin and colleagues [56] con-
ducted an analysis through an IPCW Cox model to adjust
for the effects of treatment crossover, demonstrating at a
median follow-up of 64 months that patients initially ran-
domly assigned to receive letrozole had hazard ratios of
0.52, 0.51, and 0.61 for DFS, distant DFS (DDFS), and OS,
respectively (all P <0.0001).
Exploratory and subgroup analyses of MA.17 showed
that letrozole had similar benefits in older (>70 years, n =
1,323, 26%) versus younger (<60 years) patients without
any increase in toxicity compared with placebo. Women
who were pre-menopausal at diagnosis but who became
post-menopausal during the initial 5 years (n = 889) expe-
rienced significantly greater benefit on letrozole (hazard
ratio for DFS = 0.25) than older/post-menopausal women
(n = 4,277) (hazard ratio = 0.69, P = 0.02 for interaction)
[103]. Therefore, pre-menopausal BC patients who have
become menopausal by the end of adjuvant tamoxifen also
benefit significantly from extended adjuvant therapy.
The optimal duration of extended adjuvant endocrine
therapy remains unclear. An exploratory analysis con-
ducted by Ingle and colleagues [104] suggested that the
hazard ratio continues to fall for DFS and DDFS but not
for OS out to 48 months, indicating that the benefit of
letrozole increases with longer exposure.
The 66% crossover rate in MA.17 from placebo to
letrozole after unblinding offered a good opportunity
to test whether delayed initiation of an AI could still
be of any benefit [105]. At the time of trial unblind-
ing, 1,579 women initially on placebo elected to re-
ceive letrozole and 804 women chose no further
treatment. At a median follow-up of 5.3 years, a sig-
nificant reduction in recurrence risk (adjusted hazard
ratio = 0.37, P <0.0001) and a significant 61% im-
provement in DDFS were found in patients who
switched to letrozole, although they had more adverse
prognostic factors. These results suggest that therapygiven more than 7 years after diagnosis can change
the chronic relapsing behavior of HR+ BC. They also
show that delayed letrozole commencement after
stopping tamoxifen can still be of benefit.
Other extended adjuvant therapy trials with aromatase
inhibitors
Other trials have been conducted to investigate the role
of extended adjuvant AI therapy (Table 1). In the
ABCSG Trial 6a, HR+ post-menopausal patients who
were disease-free after 5 years of adjuvant tamoxifen
(with or without AG) were randomly assigned to 3 years
of anastrozole or no further treatment [51]. With 856
patients and a median follow-up of 62.3 months, ana-
strozole further reduced the risk of a BC event (locore-
gional recurrence, distant recurrence, or contralateral
BC) by 38% versus no further treatment (hazard ratio =
0.62, P = 0.031). There was no statistically significant dif-
ference in OS between the two arms.
NSABP-B33 investigated extended adjuvant therapy
with exemestane in post-menopausal women with clin-
ical T1-3N1M0 BC who were disease-free after 5 years
of adjuvant tamoxifen [52]. This trial closed prematurely
after the publication of the results of MA.17. At 30
months of median follow-up, ITT analysis showed a
trend of improvement in 4-year DFS (91% versus 89%;
relative risk 0.68; P = 0.07) and a statistically significant
improvement in 4-year recurrence-free survival (96%
versus 94%; RR = 0.44; P = 0.004).
The Adjuvant post-Tamoxifen Exemestane versus Noth-
ing Applied trial compared exemestane versus observation
after 5 years of previous tamoxifen [106]. This trial was
prematurely closed after recruiting only 448 patients.
The data sets from these trials have been analyzed in
an EBCTG meta-analysis [107]. At a median follow-up
of 2.5 years, extended adjuvant AI treatment was associ-
ated with an absolute 2.9% decrease in BC recurrence
(relative decrease of 43%, P <0.00001) and an absolute
0.5% decrease in BC mortality (relative decrease of 27%,
P = 0.11). Of note, the authors emphasized that the mag-
nitude of the effects seen on DFS and OS in these ana-
lyses is likely underestimated because of some crossover
after unblinding.
Ongoing studies
Several ongoing studies are investigating extended AIs in
regard to optimal duration, intermittent versus continu-
ous use, and benefit after AIs used during the first 5
years of therapy (Table 5) [108].
Tamoxifen beyond 5 years
Results of relatively small trials assessing tamoxifen
treatment for more than 5 years were inconclusive
until recently [109-112]. The large Adjuvant Tamoxifen:
Table 5 Ongoing clinical trials of extended aromatase inhibitor therapy
Study Number Population (treatment received pre-enrollment) Arms at random assignment Study number
MA.17R 1,918 Prior 4.5-6 years of AI, with or without prior Ta L (5 years) versus placebo (5 years) NCT00754845
Completed AI ≤2 years prior random assignment
SALSA 3,486 Any endocrine therapy (5 years) A (5 years) versus A (2 years) NCT00295620
LEAD 4,050 T (4-6 years) L (5 years) versus L (2-3 years) NCT01064635
DATA 1,900 T (2-3 years) A (6 years) versus A (3 years) NCT00301457
NSABP-B42 3,966 AI or T→AIb (to 5 years) L (5 years) versus placebo (5 years) NCT00382070
SOLE 4,800 Any endocrine therapyc (5 years) L (5 years) versus intermittentd L (5 years) NCT00553410
aIncluding as part of MA.17. bTamoxifen must have been up to 3 years and may not have been given during years 4 and 5 of the 5 years of adjuvant hormonal
therapy. cMust have completed 4 to 6 years of prior selective estrogen receptor modulators or aromatase inhibitors (AIs), or a sequential combination of both.
When calculating 4 to 6 years, neoadjuvant endocrine therapy should not be included. dIntermittent: 48 months over 5 years: 4 × 9 months (9 months followed
by 3-month treatment-free interval in years 1 to 4, at least 36 months) plus 1 × 12 months in years 5 at least 48 months.→, switch to; A, anastrozole; DATA,
Different Durations of Anastrozole after Tamoxifen trial; L, letrozole; LEAD, Letrozole Adjuvant Therapy Duration trial; NSABP, National Surgical Adjuvant Breast and
Bowel Project; SALSA, Secondary Adjuvant Long-term Study with Arimidex trial; SOLE, Study of Letrozole Extension trial; T, tamoxifen.
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certainty, and results on 6,846 women with ER+ disease
randomly assigned to continue tamoxifen treatment to
10 years or not (control group) showed that 10 years of
tamoxifen further reduced the risk of relapse (P = 0.002),
BC mortality (P = 0.01), and all-cause mortality (P =
0.01) compared with 5 years [113]. Most of this benefit
seemed to accrue late, and there were only modest re-
ductions in recurrence rates during the 5 extra years of
tamoxifen and a more impressive carryover benefit dur-
ing the 5 years of follow-up after completion of 10 years
of tamoxifen (Table 6). Furthermore, reduced mortality
was apparent only after completion of 10 years of tam-
oxifen. Thus, the benefit of continuing tamoxifen for a
further 5 years is the sum of the carryover benefit from
the first 5 years and the sequential benefit of a further 5Table 6 Clinical trials testing tamoxifen beyond 5 years





6,846a Pre- and post-menopausal women with
ER+ EBC who already received T for
5 years (in the context of ATLAS









6,953 Invasive EBC who had already been
taking T for 5 years. 2,755 ER+ (39%) and
4,198 ER untested (61%) (estimated 80%














aAnalysis of estrogen receptor-positive (ER+) patients only; bfigures are derived from
Oncology meeting 2013 available online; cIPCW (inverse probability of censoring we
Against Shorter; aTToM, Adjuvant Tamoxifen-To Offer More?; BC, breast cancer; CI, cyears, giving a total estimated relapse risk reduction of
39% (P <0.0001) and risk reduction of BC mortality
of 36% (P <0.0001). After completion of 10 years of
tamoxifen, this estimated risk was reduced by 30% for
relapse (2P = 0.01) and 48% for mortality (2P <0.0001),
continuing for at least 5 years. These carryover benefits
contribute substantially to the cumulative benefits of
treatment, particularly because toxic effects occur
mostly during the active treatment period. The most
important AEs were an increased risk of endometrial
cancer (RR = 1.74) and PE (1.87) after 10 years of
treatment. Reassuringly, no increase was noted in stroke
incidence, and a decrease in incidence of ischemic
heart disease was noted (0.76). Overall the benefits of
extended tamoxifen seemed to substantially outweigh
the risks.Disease-free survival
hazard ratio (95% CI)
Overall survival





5-9 years RR 0.90
(0.79-1.02) P = 0.10 > 10 years RR 0.75
(0.62-0.90) P = 0.01
BC mortality: 5-9 years RR
0.97 (0.79-1.18) P = 0.74 BC
mortality: >10 years RR 0.71
(0.58-0.88) P = 0.002
All years log-rank = 0.002





RR 0.85 (0.76-0.95) P = 0.003 BC mortality: 5-9 years RR
1.08 (0.85-1.38)
Absolute reduction 4% BC mortality: >10 years RR
0.75 (0.63-0.90) P = 0.007 BC
mortality: all years RR 0.88
(0.74-1.03) P = 0.1
s 5 NA BC mortality: 5-9 years RR
0.97 (0.84-1.15)
BC mortality: >10 years RR
0.75 (0.65-0.86) P = 0.00004
BC mortality: all years RR
0.85 (0.77-0.94) P = 0.001
the abstract [114] and the presentation at American Society of Clinical
ighted) estimate of the effect in ER+. ATLAS, Adjuvant Tamoxifen: Longer
onfidence interval; EBC, early breast cancer; RR, rate ratio; T, tamoxifen.
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(aTTom) trial randomly assigned 6,953 UK women in re-
mission after 5 years of tamoxifen to 5 more years of tam-
oxifen or to stop (Table 6) [114]. The compliance rate was
75% in the 10-year tamoxifen study arm. The BC recur-
rence rates were 16.7% in the 10-year study group and
19.3% in the 5-year study group. Similarly to the ATLAS
trial, there was a time-dependent reduced risk of recurrence
with 10 years of tamoxifen with RRs of 0.99 during years 5
to 6, 0.84 during years 7 to 9, and 0.75 subsequently. Lon-
ger treatment also reduced BC mortality in a time-
dependent fashion with RRs of 1.03 during years 5 to 9 and
0.77 later and overall mortality RRs of 1.05 during years 5
to 9 and 0.86 later. Non-BC mortality was little affected
(457 versus 467 deaths; RR = 0.94). The most serious AE of
long-term tamoxifen was an increase in endometrial cancer
risk: there were 102 versus 45 endometrial cancers (RR =
2.20, P <0.0001) with 37 (1.1%) versus 20 (0.6%) deaths (ab-
solute hazard 0.5%, P = 0.02). The pooled analysis of the
UK aTTom and the international ATLAS trials showed en-
hanced significance of recurrence (P <0.0001), BC mortality
(P = 0.002), and OS (P = 0.005) benefits [114].
In conclusion, in ER+ disease, continuing tamoxifen to
year 10 rather than just to year 5 produces further reduc-
tions in recurrence, from year 7 onward, and BC mortality
after year 10. Taken together with the reduction in BC
deaths seen in trials of 5 years of tamoxifen versus none,
these results indicate that adjuvant tamoxifen for 10 years,
compared with no tamoxifen, reduces BC mortality by
about one third in the first 10 years after diagnosis and by
half subsequently. No significant heterogeneity was ob-
served in the proportional risk reduction with respect to
patient or tumor characteristics or site of first relapse.
The important questions of which patients really benefit
and whether extended adjuvant endocrine therapy should
be with tamoxifen or an AI in post-menopausal women
currently remain unanswered. Active research is currently
ongoing on molecular features and gene expression scores
combined with standard clinico-pathological criteria to
tailor extended endocrine therapy [115].
Conclusions
Adjuvant endocrine therapy significantly reduces the risk
of recurrence and death in women with early HR+ BC.
In pre-menopausal women, tamoxifen and OvS are of
similar benefit. Currently there is no strong evidence
that combined treatment is better than either alone, but
results of two major trials addressing the value of add-
itional OvS are awaited. In post-menopausal women, AIs
are significantly more effective than tamoxifen in pre-
venting recurrence but so far only letrozole has been
shown to have survival benefit. For women at only low
or moderate risk, there is little difference in efficacy be-
tween the two treatments.Extended adjuvant endocrine therapy with an AI
(post-menopausal) or tamoxifen beyond an initial 5 years
of tamoxifen further reduces the risk of relapse. The
relative merits of these two approaches and the selection
of patients requiring long-term endocrine therapy are
now important questions requiring further research, as
is the important issue of the optimum duration of an AI
if started upfront rather than after tamoxifen.
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